Mind Medicine MindMed (MNMD)
(Delayed Data from NSDQ)
$8.40 USD
+0.06 (0.66%)
Updated May 22, 2024 04:00 PM ET
After-Market: $8.39 -0.01 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Mind Medicine (MindMed) Inc. [MNMD]
Reports for Purchase
Showing records 1 - 20 ( 72 total )
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Oncology Event: The Rise of PRAME-Targeted Therapies
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaway From Biotech Breakthroughs Psychiatry Event
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Longer-Term Phase 2 Data Increases Confidence in Anxiety Program; Expect Phase 3 Program Start in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Durable MM120 Delivers 12-Week Data Solid As 4-Week Data in GAD, Gets BTD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q23 Results; Expect Lead Psychedelic MM-120 to Advance to Phase 3 in Anxiety in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Expecting Substantial MM120 Progress Over 2024, Funded Into 2026
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
MM-120 Progressing Toward Phase 3 Development in Anxiety Following Robust Phase 2b Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Topline Phase 2b Data Demonstrate Clear MM-120 Benefit in Treating GAD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Phase 2b Trial Evaluating MM-120 in Anxiety Meets Primary Endpoint; on Track for Phase 3 Start in 2H24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Psychedelic MM-120 on Track For Phase 2b Data in Anxiety by Year-End; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Clinical Data Trial Starts Coming In 4Q23/1Q24, Funded Into 2026
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Key Takeaways From 25th Annual Global Conference: Multiple Underappreciated Programs to Shine in 2H23 and 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Clinical Data Catalysts More Coming In 4Q23/1Q24, Funded Into 1H25
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Broad Pipeline Progress; Phase 2 Readouts on Track For 4Q23 and 1Q24; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From Recent Conferences: Nearing a Psychedelic Breakout With Plethora of Catalysts; LP352 to Shine in Epilepsy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P
Company: Mind Medicine (MindMed) Inc.
Industry: Medical - Biomedical and Genetics
MM-120 Appears Poised to Shine in Phase 2b Anxiety Trial Later in 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TRUCCHIO P